no weight loss tirzepatide regain after the withdrawal of (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the SURMOUNT-4 trial indicated. Read more at: https://www.medpagetoday.com/endocrinology/obesity In adults with obesity but

For many people, acid reflux is most common when first starting the medication or when increasing the dose

Schedule Regular Doctor Appointments Schedule regular follow-up appointments with your healthcare provider to assess your progress, address any concerns, and make necessary adjustments to the transition plan

Shares of the company climbed more than 200% last year, and the stock is already up more than 100% this year despite Friday's move

doi: 10.1186/s13098-025-01903-5, 27

Abstract Enteroendocrine L-cell derived peptide hormones, notably glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), have become important targets in the treatment of type 2 diabetes, obesity and intestinal diseases

That can create a diet that's low in protein, low in fiber, low in micronutrients, and inconsistent from day to day